The present invention relates to a disposable test device for detecting a target analyte in a liquid sample derived from biological specimen, e.g. saliva, urine, blood or the like. In particular, the invention relates to test devices containing test strips suited for carrying out lateral flow immunoassays.
Immunoassays are widely used to detect a substance of diagnostic interest in a sample by means of the binding of an antibody to its antigen. Monoclonal antibodies are preferred in view of their specificity and selectivity Immunoassays are routinely used, for example, for the diagnosis of a number of disease including HIV, influenza, hepatitis B or C, autoimmune diseases, neoplasias, etc., as well as for measuring any analyte against which an antibody-antigen reaction may be established. Examples of said analytes include hormones, drugs, markers, proteins, and the like.
Labelled antibodies or antigens are generally used in immunoassays to reveal the presence of a given analyte in the sample. The label is mostly conjugated to an antibody that binds to the analyte. The type of label used may vary, and may include visually detectable labels as well as labels that require instrumentation for detection. Examples of said labels include colloidal gold, enzymes, radioisotopes, fluorescent molecules or other chromophores.
A particularly convenient format for immunoassays is provided by the so-called lateral flow or flow through assays disclosed for instance in U.S. Pat. No. 5,714,389 and in U.S. Pat. No. 5,989,921.
In lateral flow assays, a liquid containing an analyte of interest migrates by capillary force along a membrane strip having suitable reagents impregnated thereon. The liquid sample, applied to one end of the strip, is eluted to a detection zone where a second antibody, immobilized on the strip, allows the visualization of the diagnostic test. Lateral flow assays may be easily carried out in a short time even in non specialized environments and are characterised by high accuracy and sensitivity.
Lateral flow assays may be of the “competitive” or “non-competitive” type. In the competitive-type immunoassays, analyte in a sample is mixed with analyte conjugated to a detectable label. The mixture then migrates along a membrane where the analyte in the sample and the labelled analyte compete for binding to a binding agent specific for the analyte immobilized on the test strip. The amount of labelled analyte detected at the detection zone is inversely proportional to the concentration of analyte in the sample. In “non-competitive”, also known as “sandwich”-type immunoassays, the analyte in the sample binds to a first binding reagent conjugated to a label. The sample containing the complex analyte-labelled binding reagent antigen is then contacted with a test strip on which the complex binds to a second binding reagent immobilized on the membrane. In correspondence of the zone where the complex is captured by the second binding reagent, a visual signal appears. Several devices for lateral flow immunoassays have been disclosed. They typically employ different absorbent materials and a membrane, usually a nitrocellulose membrane. Lateral flow devices may be configured so as to have the labelled reagent adsorbed on the test strip so that no further reagent or eluent is required, the liquid sample acting as an eluent. This kind of devices may be convenient when the liquid sample is easy to collect and available in large amounts, for instance in the case of pregnancy tests to be carried out on urine. For other types of assays, an eluent such as a buffer is required. The labelled reagent, instead of being adsorbed on the strip, may also be added to the liquid sample prior to contacting the sample to the test strip.
The assays requiring a separate liquid reagent, such as a buffer system, may be difficult to perform outside an equipped laboratory, by non trained users who are required to measure precise volumes of reagent and or suspend samples to be applied on the test strip. In order to overcome this drawback, a number of devices have been proposed wherein a portion of the test strip is configured so as to form a container or reservoir containing the liquid reagent, with the purpose of avoiding the operations of sampling and measuring the liquid reagent. The known devices are however cumbersome since the containers linked to the test strip are liable to leakage of the fluid contained therein, as a consequence of the geometry intrinsic to the devise hosting the test strip itself.
Most known lateral flow assays have to be directly contacted with the physiological fluid (blood, saliva, urine, etc) and this may be again a potential source of problems for inexpert users.
WO 2009/027935 A2 discloses a chemical sensor cartridge, preferably consisting of two parts, comprising a sample collection element made integral with one part of the cartridge, a sensor element realized by a biosensor chip, a sensor transportation mechanism for transporting sample from the sample collection element to the sensor element, and a connector for linking the sensor element to an external reader device for reading out the sensed parameter.
U.S. Pat. No. 7,473,563 B2 discloses a sampling and testing device including a sampling member, defining a reservoir that stores an elution solvent, slideably engaged with a base that contains a lateral flow strip adapted to detect specific analytes of interest. During slideable withdrawal of the sampling member from the base, the elution solvent is automatically released to a wick assembly of the sampling member, which is returned to the base after sampling an environment surface for an analyte of interest.
An object of the invention is to provide a disposable test device that overcomes the above mentioned drawbacks of known devices and which is simple to use by personnel with no specialized training, has a simple and inexpensive construction and is suitable to make different tests simultaneously on a bodily fluid.
Another object of the invention is to provide a disposable test device allowing an easy sampling of the physiological fluid containing the analyte of interest, increasing thereby the test accuracy and sensitivity, allowing the fluid to be concentrated on a separate member of the device suited also for in vivo diagnostic procedures.
These objects are achieved by the disposable test device according to the present invention which comprises the features listed in the appended independent claim 1.
The invention relates also to a method of operation of such a test device, according to claim 14.
Preferred embodiments of the invention are disclosed in the dependent claims.
Essentially, the disposable test device according to the invention comprises: a reagent container, a test chamber and a sample loading devise that can be in the form of a pill.
The reagent container is in the form of a cylinder open at one end, wherein a perforated piston of elastic material, such as rubber, can slide. The open end of the container can be closed by a sealing foil to prevent any potential loss of reagent.
The test chamber comprises an outer tubular housing, an inner support member and at least one, preferably a plurality of test strips interposed between the inner support member and the outer housing.
During use, the sample loading pill, which contain absorbent material, previously impregnated with bodily fluid, is sandwiched between the test chamber and the reagent container, from which the sealing foil has been removed, and the bodily fluid mixed with the reagent is transferred to the test strips.
The loading pills are particularly convenient for testing analytes contained in the saliva since they may be ingested by the subjects in need of a diagnosis and kept in the mouth for a period of time sufficient to capture the analyte. This test would be particularly convenient, for instance, in the diagnosis of influenza type A and/or type B infections where the viral antigens are present in minute amounts in the saliva of infected subjects. A variety of clinical condition and infective diseases may also be effectively diagnosed by means of the devices of the invention. Other examples of analytes which may be conveniently detected in the saliva or other physiological fluids (e.g. sweat) include drugs of abuse (cocaine, heroin, amphetamines, barbiturates, benzodiazepines, methadone) and anabolising steroids.
The pills may consist of any suitable absorbent material, typically synthetic, semi-synthetic or natural polymers. Preferred materials include protein matrices (silk, wool) sephadex, cellulose derivatives such as ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, in admixtures with lubricants, tabletting agents, surfactants and other conventional excipients.
The size of the pill is not critical and will depend on the specific test for which it has been designed. Anyhow, a length of 10-15 mm and a few mm of diameter will be suited for most applications.
In a preferred embodiment, the sample collection sample loading pill comprises a hollow outer shell molded in soft material such as silicone having an ogival shape, filled with adsorbent material either inert to carry biological samples or chemically derivatized to selectively enrich the analytes to be measured.
Further features of the invention will appear from the following detailed description of purely illustrative and therefore not limitative embodiments thereof made in conjunction with the attached drawings, wherein:
a)-f) are diagrammatic sectional views showing successive steps during operation of the device;
In the following description similar reference numerals refer to similar parts in the different drawings.
Referring to
The reagent container 10 (see in particular
After the container 10 has been filled until the top of the piston is level with open end 12 of the container, the syringe is extracted and the hole made by the syringe needle is hermetically sealed by the elasticity of the rubber piston 13. As a precautionary measure, a sealing foil 14 is heat stacked onto the open end of the container preventing any potential loss of reagent in storage.
Referring now to
The proximal end 28 of the test strips 26 is inwardly folded about 90° such that after being positioned on the inner support member 23 and inserted into the outer housing 21 from the open distal end thereof, they are pushed to form an intimate contact with the absorbent pad 27.
From the proximal end 29 of the outer housing 21 projects a short tubular portion 31, preferably of circular section, having a diameter less than the outer contour of the housing 21 and such as to tightly slide into the reagent container 10.
The sample loading pill 30 is formed of absorbent material which can be used orally or in any other suitable way.
Referring now to
The pill 30 is submerged in the sample and inserted into the tubular portion 31 of the test chamber until it forms an intimate contact with the absorbent pad 27 (
Thereafter, the sealing foil 14 is removed from the reagent container 10 and the reagent container is mated with the tubular portion 31 of the test chamber (
The piston 13 inside the reagent container 10 is pushed backwards by the tubular portion 31 and the reagent moves towards the sample loading pill 30 through the central hole previously made by the syringe needle in the piston 13 (
The reagent pushes through and over the sample loading pill 30 and moves the sample which is impregnated in the sample loading pill towards the absorbent pad 27 (
The capillary test strips 26 transport the test reagent through them and a detection signal line 35 which is printed on the test strips becomes visible.
The device of the invention, in particular the test chamber 20 can be of any suitable shape. By way of example only, the embodiments of
The reagent chamber also could be of any convenient shape, although it is preferred a circular cross-section for a better sliding of the piston 13 therein.
In the foregoing description, the terms “proximal” and “distal” are referred to the right part of the drawings, i.e. with respect to the reagent chamber 10.
According to this embodiment, the tubular portion 31 projects from the proximal end of the inner support member 23 and the proximal end 28 of the test strip 26 is inwardly folded about 180° to be in direct contact with the sample loading pill 30 when the device is assembled, without any extra absorbent pad between the sample loading pill 30 and the test strips 26.
The outer housing 21 has the distal end closed wherein a vent hole is provided and the proximal end opened for insertion of the inner support member 23. An enlarged tubular portion 32 projects from the proximal end of the outer housing 21 to at least partially cover the reagent container 10 when it is inserted on the tubular portion 31 of the inner support member 23 (
For collecting a sample of saliva the sample loading pill is inserted as a whole into the mouth of the patient and by biting and sucking on it for a defined period of time, the absorbent material 30″ fills with the sample.
The elasticity of the outer shell 30′ allows an easy insertion of the sample loading pill 30 into the tubular portion 31 of the test chamber and when the reagent container 10 is mated with the tubular portion 31, as shown e.g. in
The following examples illustrate typical tests which can be carried out with the device according to the invention.
Influenza test involves the extraction of influenza A and B viral antigen. The specimen is collected by a sterile pill which is kept in the mouth for 5 min. The viral antigens is adsorbed on the sterile pill. The strip is contained in a device cassette.
An antibody specific for the target of interest (anti NP A, anti NPB, HA or NA) is immobilized on a nitrocellulose membrane in the form of a line, called the test line.
A secondary antibody against the primary antibody, generally an anti mouse IgG, is also immobilized on the nitrocellulose membrane in the form of a line called the control line.
Gold nanoparticles conjugated with analytical specific antibody are pre adsorbed into the conjugated pad.
The sample loading pill is then placed onto the housing (just over the sample pad strip) and after the contact with the specific extraction buffer, the virus particles are disrupted. Through capillary action, the antigens (NPs, HA and NA) are transported into the conjugate pad, where bind gold nanoparticles antibody conjugated (GNP-mAb).
On the test line the anti influenza antibody catches the GNP-mAb coated with antigens, while the second antibody (anti mouse IgG) catches particles which did not bind to an analyte on the control line.
If influenza A or B antigens are present will appear a specific red line together with a positive control line, if influenza antigens are not present will appear just the positive control line.
This immunoassay format described above, can be also applied for a malaria lateral flow test. As the test sample (blood or serum) flows through the membrane the antigen HRP-2, or other specific malaria proteins, bind the gold nanoparticles monoclonal antibody conjugated.
This complex moves further on the membrane to the test region where it is immobilised by the anti HRP-2 (monoclonal) coated on the membrane.
The formation of a colored band confirms a positive test result. The absence of the colored band in the test region indicates a negative test result. The unreacted conjugate move and subsequently immobilised by anti mouse antibodies coated on the membrane at the control region, forming a red band.
Competitive immunoassay: when the target analytes consist of small molecules, as in the case of drugs of abuse, competitive assays are often preferred.
After the extraction of the sample form the pill the analyte are transported into the conjugate pad. The conjugate pad contains antibodies that are already bound to an analogue of the target analyte.
If the target analyte is present in the sample it will therefore not bind with the conjugate and will remain unlabelled. As the sample migrates along the membrane and reaches the capture zone an excess of unlabelled analyte will bind to the immobilised antibodies and block the capture of the conjugate, so that no visible line is produced. The unbound conjugate will then bind to the antibodies in the control zone producing a visible control line. A single control line on the membrane is a positive result. Two visible lines in the capture and control zones is a negative result.
Of course the invention is not restricted to the embodiments previously described and shown in the appended drawing, instead many modifications and changes can be made, falling within the scope of protection defined by the appended claims.
Number | Date | Country | Kind |
---|---|---|---|
12177471.5 | Jul 2012 | EP | regional |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP2013/065392 | 7/22/2013 | WO | 00 |